zaptuximab lentiviral gene therapy (Chinese Academy of Medical Sciences)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namezaptuximab lentiviral gene therapy (Chinese Academy of Medical Sciences)
Drug Alias Nameanti-DR5 lentiviral gene therapy (Chinese Academy of Medical Sciences)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vector
Mechanisms of ActionTumor necrosis factor receptor superfamily member 10B agonists
TargetsTumor necrosis factor receptor superfamily member 10B
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesChinese Academy Of Medical Sciences
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesChinese Academy Of Medical Sciences
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A